Axsome Therapeutics (NASDAQ:AXSM) issued its earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.01, MarketWatch Earnings reports.
Shares of NASDAQ:AXSM traded up $0.03 on Friday, reaching $10.74. The company’s stock had a trading volume of 16,575 shares, compared to its average volume of 2,634,489. Axsome Therapeutics has a 52-week low of $1.94 and a 52-week high of $10.89. The company has a debt-to-equity ratio of 6.00, a quick ratio of 1.46 and a current ratio of 1.46. The stock has a market capitalization of $302.90 million, a price-to-earnings ratio of -8.67 and a beta of 3.32.
A number of research firms have recently commented on AXSM. HC Wainwright restated a “buy” rating and set a $18.00 target price (up from $15.00) on shares of Axsome Therapeutics in a research report on Friday. They noted that the move was a valuation call. Cantor Fitzgerald lifted their price target on shares of Axsome Therapeutics from $13.00 to $16.00 and gave the company an “overweight” rating in a research report on Friday. BidaskClub raised shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday. BTIG Research lifted their target price on shares of Axsome Therapeutics to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 8th. Finally, ValuEngine upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $24.75.
ILLEGAL ACTIVITY NOTICE: “Axsome Therapeutics (AXSM) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://sportsperspectives.com/2019/03/15/axsome-therapeutics-axsm-posts-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Read More: Insider Trading
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.